Table 1.
The key traits and the quality evaluation of the included researches
| Study (Year) | Country | Time | N | High NLR | M/F | Age(year) | NLR cut-off | Median survival(year) | Postoperative chemotherapy | Follow-up (months) | Outcome | NOS | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verter (2021) [12] | Israel | 2005–2017 | 231 | 53 | 131/100 | 66.3a | 3 |
NLR ≤ 3 NLR > 3 |
OS 5.2 3.8 |
DSS 6.5 4.2 |
RFS 1.2 0.8 |
Neoadjuvant chemotherapy (n = 175) Adjuvant chemotherapy (n = 166) |
180 | OS/DSS/RFS | 8 |
| Wang (2019) [24] | China | 2002–2016 | 452 | – | 289/163 | 57b | 2.6 | – | Postoperative chemotherapy (n = 284) | 84 | OS/DFS | 8 | |||
| Kim (2019) [3] | Korea | 2005–2015 | 83 | 41 | 62/21 | 59.5a | 1.94 |
NLR < 1.94 NLR ≥ 1.94 |
OS 6.5 3.4 |
DFS 2.5 1.1 |
5-FU plus LV (n = 6) FOLFOX (n = 32) FOLFOX plus Beva (n = 2) FOLFIRI (n = 30) FOLFIRI plus Beva (n = 8) FOLFIRI plus Cetu (n = 5) |
140 | OS/DFS | 7 | |
| Neal (2015) [25] | UK | 2006–2010 | 302 | 53 | 192/110 | 59.5a | 3 |
NLR < 5 NLR ≥ 5 |
OS 3.3 2.3 |
CSS 3.8 2.3 |
Neoadjuvant chemotherapy (n = 126) | 96 | OS/DFS | 8 | |
| Neal (2011) [26] | UK | 2000–2006 | 202 | 28 | 126/76 | 61.5a | 5 | – | Neoadjuvant chemotherapy (n = 84) | 70 | OS/DFS | 7 | |||
| Neal (2009) [27] | UK | 2000–2005 | 174 | 21 | 106/68 | 65b | 5 | – | Adjuvant chemotherapy (n = 67) | 69 | OS/DFS | 7 | |||
| Mao (2019) [28] | China | 2006–2015 | 183 | 104 | 123/60 | 60b | 2.3 |
NLR ≤ 2.3 NLR > 2.3 |
OS 3.6 2.6 |
RFS 0.9 0.5 |
Postoperative chemotherapy (n = 143) | 69 | OS/RFS | 8 | |
| Halazun (2008) [29] | UK | 1996–2006 | 440 | 78 | 289/151 | 64a | 5 |
NLR < 5 NLR ≥ 5 |
OS 4.5 2.2 |
DFS 2.9 1.1 |
5-FU plus CF (n = 440) | 97 | OS | 8 | |
| Erstad (2020) [30] | US | 1995–2017 | 151 | 40 | 84/67 | 64a | 5 |
NLR < 5 NLR ≥ 5 |
OS 6.3 3.1 |
– | 186 | OS | 7 | ||
| Neofytou (2014) [31] | UK | 2005–2012 | 140 | 63 | 88/52 |
≤ 70 (n = 109) > 70 (n = 31) |
2.4 |
NLR ≤ 2.4 NLR > 2.4 |
OS c 4.6 |
DFS 1.4 0.9 |
neoadjuvant chemotherapy (n = 140) | 103 | OS/DFS | 7 | |
| Peng (2017) [32] | China | 2000–2012 | 150 | 16 | 97/53 | 58b | 4.63 |
NLR < 4.63 NLR ≥ 4.63 |
OS 3.7 1.5 |
RFS 1.9 0.7 |
postoperative chemotherapy (n = 110) | 126 | OS/RFS | 7 | |
| Zeman (2013) [33] | Poland | 2001–2009 | 96 | – | – | – | 5 |
NLR ≤ 5 NLR > 5 |
DFS 1.8 1 |
5-FU plus LV (n = 20) FOLFOX (n = 5) Adjuvant chemotherapy (n = 25) |
156 | DFS | 8 | ||
| Giakoustidis (2015) [34] | UK | 2005–2012 | 169 | 71 | 104/65 |
≤ 70 (n = 135) > 70 (n = 34) |
2.5 |
NLR ≤ 2.4 NLR > 2.4 |
OS c 6.3 |
Oxaliplatin-based chemotherapy (n = 111) Irinotecan- based chemotherapy (n = 52) Other (n = 6) |
101 | OS/DFS | 7 | ||
| Wu (2016) [35] | China | 2008–2013 | 55 | 14 | 35/20 | 59b | 4 |
NLR < 4 NLR ≥ 4 |
OS c 1.5 |
PFS 1 0.6 |
mFOLFOX6 (n = 21) XELOX (n = 34) |
80 | OS/PFS | 7 | |
| Hamada (2020) [21] | Japan | 2000–2008 | 29 | 3 | 20/9 | 63 | 4.1 | – |
mFOLFOX6 (n = 21) XELOX (n = 34) |
97 | OS | 7 | |||
| Zhang (2012) [36] | China | 2000–2008 | 92 | 21 | 61/41 |
≤ 65 (n = 48) > 65 (n = 44) |
5 |
NLR ≤ 5 NLR > 5 |
OS 3.5 2.2 |
DFS 2.1 0.9 |
– | 70 | OS/DFS | 7 | |
| Weiner (2018) [37] | US | – | 131 | – | 84/47 | – | 5 |
NLR < 5 NLR ≥ 5 |
OS 1.1 0.7 |
– | – | OS | 7 | ||
| Tohme (2014) [38] | US | 2002–2012 | 104 | 48 | – |
< 70 (n = 61) ≥ 70 (n = 43) |
5 |
NLR < 5 NLR ≥ 5 |
OS 1.1 0.7 |
– | 70 | OS | 7 | ||
M: male; F: female; a: mean age; b: median age; c: median OS was not reached in patients; 5-FU: 5-fluorouracil; LV: leucovorin; FOLFOX: 5-fluorouracil, leucovorin and oxaliplatin; Beva: bevacizumab; FOLFIRI: 5-fluorouracil, leucovorin and Irinotecan; Cetu: cetuximab; CF: folinic acid; mFOLFOX6: folic acid/fluorouracil plus oxaliplatin; XELOX: capecitabine plus oxaliplatin; CSS: Cancer-specific survival; PFS: Progression-free survival. “—”: no data